One evening in 1981 James "Bryant" Neville, Jr., a 17-year-old high school junior, was driving his truck down a dark country ...

As we wrap up our series on childhood vaccinations and the recommendations to get them, we want to consider with you more ...

In new results from a clinical trial, researchers show that electrical stimulation of the spinal cord can restore the muscle ...

New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene ...

When a two-year-old boy suffered a catastrophic injury that severed the connection between his skull and spine, doctors across Europe told his family there was no hope. His spinal cord was completely ...

There is a new hope for people with spinal cord injuries. Doctors are using an experimental, easy to deliver drug, with surprising results. A Chicago are a patient who got the drug says it’s nothing ...

Add Yahoo as a preferred source to see more of our stories on Google. There is a new hope for people with spinal cord injuries. Doctors are using an experimental, easy to deliver drug, with surprising ...

KUTV — For patients suffering from chronic, severe back pain that hasn’t responded to traditional treatments, a spinal cord stimulator (SCS) may offer new hope. Dr. Jeff Pence, Interventional Spine ...

Vertebral hemangiomas (VH), the most prevalent benign spinal tumors, often remain asymptomatic for many years or even a lifetime. Symptomatic cases are rare, constituting only 0.9%–1.2% of cases.

Timed release of therapeutic molecules from a soft nanofiber-hydrogel implant supports nerve regrowth and circuit repair after spinal injury, restoring movement and bladder control in preclinical ...

The least-squares mean difference in the Hammersmith Functional Motor Scale-Expanded change from baseline at 12 months was 1.8 points for those 2 to 12 years receiving apitegromab vs placebo.

MONDAY, Aug. 25, 2025 (HealthDay News) -- For patients with nonambulatory type 2 or type 3 spinal muscular atrophy, apitegromab, a monoclonal antibody that inhibits myostatin activation, improves ...